Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute), 22049-22050 [2023-07684]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 70 / Wednesday, April 12, 2023 / Notices
22049
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1—Continued
21 CFR section; activity
Total .....................................................................
1 There
Number of
respondents
Number of
disclosures per
respondent
Total annual
disclosures
Average
burden per
disclosure
........................
..........................
........................
..............................
1,030,270
are no capital costs or operating and maintenance costs associated with this collection of information.
These estimates reflect our continued
experience with the information
collection. We have made nominal
adjustments to reflect the addition of
burden associated with gluten and
certain bottled or otherwise packaged
beer; petition submissions received
since our last evaluation of the
information collection; and informal
communications with industry
regarding food product labeling.
Center for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Blvd., Suite 101, Bethesda, MD
20892, 301–827–4905, brownnac@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: April 7, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–07683 Filed 4–11–23; 8:45 am]
Dated: April 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4164–01–P
[FR Doc. 2023–07656 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
ddrumheller on DSK120RN23PROD with NOTICES1
Total hours
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; NCATS CTSA Training
Grants Review Meeting.
Date: May 17, 2023.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Office of Grants Management and
Scientific Review National Center for
Advancing Translational Sciences, National
Institutes of Health, 6701 Democracy
Boulevard, Suite 1001 Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Nakia C. Brown, Ph.D.,
Scientific Review Officer, Office of Grants
Management and Scientific Review, National
VerDate Sep<11>2014
19:25 Apr 11, 2023
Jkt 259001
Proposed Collection; 60-Day Comment
Request; Specimen Resource Locator
(National Cancer Institute)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide an
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health, National
Cancer Institute (NCI) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Joanne Demchok, Program
Director, Cancer Diagnosis Program,
Division of Cancer Treatment and
Diagnosis, 9609 Medical Center Drive,
Rockville, Md. 20892 or call non-tollfree number 240–276–5959 or Email
SUMMARY:
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
your request, including your address to:
peterjo@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public, and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: Specimen
Resource Locator (NCI), 0925–0703:
Expiration Date 11/30/2023,
EXTENSION, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The availability of
specimens and associated data is critical
to increase our knowledge of cancer
biology and to translate important
research discoveries into clinical
applications. The development of
molecular technologies in cancer
patients with defined molecular
abnormalities advances the
identification and development of
clinically useful biomarkers and
diagnostic assays that guide treatment.
The discovery and validation of
cancer prevention markers require
researchers’ access to quality clinical
biospecimens. In response to this need,
NCI’s Cancer Diagnosis Program
developed, and is expanding, a
searchable database: Specimen Resource
Locator (SRL) https://
specimens.cancer.gov/tissue/
default.htm. The SRL allows scientists
in the research community and the NCI
E:\FR\FM\12APN1.SGM
12APN1
22050
Federal Register / Vol. 88, No. 70 / Wednesday, April 12, 2023 / Notices
to locate specimens needed for their
research. The SRL lists all NCIsupported and non-NCI-supported
biospecimens repositories and their
links. It is not NCI’s intent to collect the
biospecimens; instead, the collections
are descriptions of the available data
that can act as a resource and be shared
with interested researchers and
scientists. This submission does not
involve any analysis.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
105.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Private Sector ...................................
State Government .............................
Federal Government .........................
Private Sector ...................................
State Government .............................
Federal Government .........................
Initial Request ..................................
Total ...........................................
...........................................................
[FR Doc. 2023–07684 Filed 4–11–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods; Notice of Public Meeting;
Request for Public Input
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) will
hold a public forum to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders. Interested persons
may attend in person or view the
meeting remotely by webcast. Time will
be set aside for questions and public
statements on the topics discussed.
Registration is requested for attending in
person and required for viewing the
webcast and presenting oral statements.
Information about the meeting and
registration are available at https://
ntp.niehs.nih.gov/go/iccvamforum2023.
SUMMARY:
Meeting: May 18 and 19, 2023,
9 a.m. to approximately 3 p.m. EDT both
days.
Registration for Onsite Meeting:
Deadline is May 17, 2023. Registration
for Webcast: Deadline is May 19, 2023.
DATES:
VerDate Sep<11>2014
19:25 Apr 11, 2023
Jkt 259001
Frm 00090
Fmt 4703
Average
burden per
response
(in hours)
Total burden
hour
1
1
1
1
1
1
30/60
30/60
30/60
5/60
5/60
5/60
35
35
30
2
2
1
........................
250
........................
105
Registration for Oral Statements:
Deadline is May 9, 2023.
Registration to attend in person is
requested; registration to view the
webcast and present oral public
statements is required.
ADDRESSES: Meeting Location: William
H. Natcher Conference Center, National
Institutes of Health (NIH), Bethesda, MD
20892. Meeting web page: Registration
and other meeting materials are at
https://ntp.niehs.nih.gov/go/
iccvamforum-2023. A preliminary
agenda will be posted on this page by
May 2, 2023.
FOR FURTHER INFORMATION CONTACT: Dr.
Nicole Kleinstreuer, Director, National
Toxicology Program Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM),
email: nicole.kleinstreuer@nih.gov,
telephone: 984–287–3150.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a
congressionally mandated committee,
coordinates the development and
validation of alternative testing
strategies that protect human health and
the environment while replacing,
reducing, or refining animal use.
ICCVAM’s goals include promotion of
national and international partnerships
between governmental and
nongovernmental groups, including
academia, industry, advocacy groups,
and other key stakeholders. To foster
these partnerships ICCVAM initiated
annual public forums in 2014 to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders (79 FR 25136).
This year’s meeting will be held on
May 18 and 19, 2023. NICEATM and
ICCVAM members will give
presentations on current activities
related to the development and
PO 00000
Number of
responses per
respondent
70
70
60
20
20
10
Annual Update .................................
Dated: April 7, 2023.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
respondents
Type of respondent
Sfmt 4703
validation of alternative test methods
and approaches.
There will be opportunities for
participants to ask clarifying or followup questions of the ICCVAM members
about their presentations. Instructions
for submitting these questions will be
provided to webcast viewers prior to the
event. The agenda will also include time
for public oral statements relevant to the
ICCVAM mission and current activities
from participants who have registered to
do so in advance.
Preliminary Agenda and Other
Meeting Information: A preliminary
agenda will be posted by May 2 at
https://ntp.niehs.nih.gov/go/
iccvamforum-2023. Interested
individuals are encouraged to visit this
web page to stay abreast of the most
current meeting information.
Meeting and Registration: This
meeting is open to the public. The
public may attend the meeting at NIH,
where attendance is limited only by the
space available, or view remotely by
webcast. Those planning to attend the
meeting in person are encouraged to
register at https://ntp.niehs.nih.gov/go/
iccvamforum-2023 by May 17, 2023, to
facilitate planning for appropriate
meeting space. Registration for the
webcast is required and is open through
3 p.m. EDT on May 19, 2023, at https://
ntp.niehs.nih.gov/go/iccvamforum2023. Registrants will receive
instructions on how to access and
participate in the webcast in the email
confirming their registration.
NIH visitor and security information
is available at https://www.nih.gov/
about/visitor/index.htm. Individuals
with disabilities who need
accommodation to participate in this
event should contact Milene Brownlow
at phone: 984–287–3364 or email:
E:\FR\FM\12APN1.SGM
12APN1
]]>Agencies
[Federal Register Volume 88, Number 70 (Wednesday, April 12, 2023)]
[Notices]
[Pages 22049-22050]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07684]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; Specimen Resource
Locator (National Cancer Institute)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide an opportunity for public comment on proposed
data collection projects, the National Institutes of Health, National
Cancer Institute (NCI) will publish periodic summaries of proposed
projects to be submitted to the Office of Management and Budget (OMB)
for review and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Joanne
Demchok, Program Director, Cancer Diagnosis Program, Division of Cancer
Treatment and Diagnosis, 9609 Medical Center Drive, Rockville, Md.
20892 or call non-toll-free number 240-276-5959 or Email your request,
including your address to: [email protected]. Formal requests for
additional plans and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written comments and/or suggestions
from the public, and affected agencies are invited to address one or
more of the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimizes the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Proposed Collection Title: Specimen Resource Locator (NCI), 0925-
0703: Expiration Date 11/30/2023, EXTENSION, National Cancer Institute
(NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: The availability of
specimens and associated data is critical to increase our knowledge of
cancer biology and to translate important research discoveries into
clinical applications. The development of molecular technologies in
cancer patients with defined molecular abnormalities advances the
identification and development of clinically useful biomarkers and
diagnostic assays that guide treatment.
The discovery and validation of cancer prevention markers require
researchers' access to quality clinical biospecimens. In response to
this need, NCI's Cancer Diagnosis Program developed, and is expanding,
a searchable database: Specimen Resource Locator (SRL) https://specimens.cancer.gov/tissue/default.htm. The SRL allows scientists in
the research community and the NCI
[[Page 22050]]
to locate specimens needed for their research. The SRL lists all NCI-
supported and non-NCI-supported biospecimens repositories and their
links. It is not NCI's intent to collect the biospecimens; instead, the
collections are descriptions of the available data that can act as a
resource and be shared with interested researchers and scientists. This
submission does not involve any analysis.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 105.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response Total burden
respondents respondent (in hours) hour
----------------------------------------------------------------------------------------------------------------
Private Sector................ Initial Request. 70 1 30/60 35
State Government.............. 70 1 30/60 35
Federal Government............ 60 1 30/60 30
Private Sector................ Annual Update... 20 1 5/60 2
State Government.............. 20 1 5/60 2
Federal Government............ 10 1 5/60 1
---------------------------------------------------------------
Total..................... ................ .............. 250 .............. 105
----------------------------------------------------------------------------------------------------------------
Dated: April 7, 2023.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer Institute, National
Institutes of Health.
[FR Doc. 2023-07684 Filed 4-11-23; 8:45 am]
BILLING CODE 4140-01-P
